Natalie Ullman

Natalie Ullman

Auto-generated profile, based on publicly available information

Natalie Ullman

Divison of Neurology, Children's Hospital of Philadelphia, PA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Lancet
Verified
Journal Article
Closed access
DHDaniel F Hanley
Daniel F Hanley
RTRichard E Thompson
Richard E Thompson
MRMichael Rosenblum
Michael Rosenblum
GYGayane Yenokyan
Gayane Yenokyan
KLKaren Lane
Karen Lane
AZAli Zomorodi
Ali Zomorodi

1 February 2017 in The Lancet
Verified
Journal Article
Closed access
DHDaniel F Hanley
Daniel F Hanley
KLKaren Lane
Karen Lane
NMNichol McBee
Nichol McBee
WZWendy Ziai
Wendy Ziai
STStanley Tuhrim
Stanley Tuhrim
IAIssam A Awad
Issam A Awad

1 November 2016 in The Lancet Neurology
Verified
Journal Article
Open access
DHDaniel F Hanley
Daniel F Hanley
RTRichard E Thompson
Richard E Thompson
JMJohn Muschelli
John Muschelli
MRMichael Rosenblum
Michael Rosenblum
NMNichol McBee
Nichol McBee
MZMario Zuccarello
Mario Zuccarello
Craniotomy, according to the results from trials, does not improve functional outcome after intracerebral haemorrhage. Whether minimally invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a good functional outcome is not known. We investigated the safety and efficacy of alteplase, a recombinant tissue plasminogen activator, in combination with minimally invasive surgery (MIS) in patients with intracerebral haemorrhage. MISTIE was an open-label, phase 2 trial that was done in 26 hospitals in the USA, Canada, the UK, and Germany. We used a computer-generated allocation sequence with a block size of four to centrally randomise patients aged 18-80 years with a non-traumatic (spontaneous) intracerebral haemorrhage of 20 mL or higher to standard medical care or image-guided MIS plus alteplase (0·3 mg or 1·0 mg every 8 h for up to nine doses) to remove clots using surgical aspiration followed by alteplase clot irrigation. Primary outcomes were all safety outcomes: 30 day mortality, 7 day procedure-related mortality, 72 h symptomatic bleeding, and 30 day brain infections. This trial is registered with ClinicalTrials.gov, number NCT00224770. Between Feb 2, 2006, and April 8, 2013, 96 patients were randomly allocated and completed follow-up: 54 (56%) in the MIS plus alteplase group and 42 (44%) in the standard medical care group. The primary outcomes did not differ between the standard medical care and MIS plus alteplase groups: 30 day mortality (four [9·5%, 95% CI 2·7-22.6] vs eight [14·8%, 6·6-27·1], p=0·542), 7 day mortality (zero [0%, 0-8·4] vs one [1·9%, 0·1-9·9], p=0·562), symptomatic bleeding (one [2·4%, 0·1-12·6] vs five [9·3%, 3·1-20·3], p=0·226), and brain bacterial infections (one [2·4%, 0·1-12·6] vs zero [0%, 0-6·6], p=0·438). Asymptomatic haemorrhages were more common in the MIS plus alteplase group than in the standard medical care group (12 [22·2%; 95% CI 12·0-35·6] vs three [7·1%; 1·5-19·5]; p=0·051). MIS plus alteplase seems to be safe in patients with intracerebral haemorrhage, but increased asymptomatic bleeding is a major cautionary finding. These results, if replicable, could lead to the addition of surgical management as a therapeutic strategy for intracerebral haemorrhage. National Institute of Neurological Disorders and Stroke, Genentech, and Codman.

1 March 2013 in Stroke
Verified
Journal Article
Closed access
PDF file
WMW. Andrew Mould
W. Andrew Mould
JCJ. Ricardo Carhuapoma
J. Ricardo Carhuapoma
JMJohn Muschelli
John Muschelli
KLKaren Lane
Karen Lane
TMTimothy C. Morgan
Timothy C. Morgan
DHDaniel F. Hanley
Daniel F. Hanley
Background and Purpose—: Perihematomal edema (PHE) can worsen outcomes after intracerebral hemorrhage (ICH). Reports suggest that blood degradation products lead to PHE. We hypothesized that hematoma evacuation will reduce PHE volume and that treatment with recombinant tissue-type plasminogen activator (rt-PA) will not exacerbate it. Methods—: Minimally invasive surgery and rt-PA in ICH evacuation (MISTIE) phase II tested safety and efficacy of hematoma evacuation after ICH. We conducted a semiautomated, computerized volumetric analysis on computed tomography to assess impact of hematoma removal on PHE and effects of rt-PA on PHE. Volumetric analyses were performed on baseline stability and end of treatment scans. Results—: Seventy-nine surgical and 39 medical patients from minimally invasive surgery and rt-PA in ICH evacuation phase II (MISTIE II) were analyzed. Mean hematoma volume at end of treatment was 19.6±14.5 cm 3 for the surgical cohort and 40.7±13.9 cm 3 for the medical cohort ( P <0.001). Edema volume at end of treatment was lower for the surgical cohort: 27.7±13.3 cm 3 than medical cohort: 41.7±14.6 cm 3 ( P 65%, 20% to 65%, and <20% ICH removed were analyzed ( P <0.001). Positive correlation between PHE reduction and percent of ICH removed was identified (ρ=0.658; P <0.001). In the surgical cohort, 69 patients underwent surgical aspiration and rt-PA, whereas 10 underwent surgical aspiration only. Both cohorts achieved similar clot reduction: surgical aspiration and rt-PA, 18.9±14.5 cm 3 ; and surgical aspiration only, 24.5±14.0 cm 3 ( P =0.26). Edema at end of treatment in surgical aspiration and rt-PA was 28.1±13.8 cm 3 and 24.4±8.6 cm 3 in surgical aspiration only ( P =0.41). Conclusions—: Hematoma evacuation is associated with significant reduction in PHE. Furthermore, PHE does not seem to be exacerbated by rt-PA, making such neurotoxic effects unlikely when the drug is delivered to intracranial clot.

1 September 2015 in Stroke
Verified
Journal Article
Open access
PDF file
AWAlastair J.S. Webb
Alastair J.S. Webb
NUNatalie L. Ullman
Natalie L. Ullman
TMTim C. Morgan
Tim C. Morgan
JMJohn Muschelli
John Muschelli
JKJoshua Kornbluth
Joshua Kornbluth
KTKristi Tucker
Kristi Tucker
Background and Purpose—: The ABC/2 score estimates intracerebral hemorrhage (ICH) volume, yet validations have been limited by small samples and inappropriate outcome measures. We determined accuracy of the ABC/2 score calculated at a specialized reading center (RC-ABC) or local site (site-ABC) versus the reference-standard computed tomography–based planimetry (CTP). Methods—: In Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for Intracerebral Hemorrhage Evacuation-II (MISTIE-II), Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-IVH) and CLEAR-III trials. ICH volume was prospectively calculated by CTP, RC-ABC, and site-ABC. Agreement between CTP and ABC/2 was defined as an absolute difference up to 5 mL and relative difference within 20%. Determinants of ABC/2 accuracy were assessed by logistic regression. Results—: In 4369 scans from 507 patients, CTP was more strongly correlated with RC-ABC ( r 2 =0.93) than with site-ABC ( r 2 =0.87). Although RC-ABC overestimated CTP-based volume on average (RC-ABC, 15.2 cm 3 ; CTP, 12.7 cm3), agreement was reasonable when categorized into mild, moderate, and severe ICH (κ=0.75; P <0.001). This was consistent with overestimation of ICH volume in 6 of 8 previous studies. Agreement with CTP was greater for RC-ABC (84% within 5 mL; 48% of scans within 20%) than for site-ABC (81% within 5 mL; 41% within 20%). RC-ABC had moderate accuracy for detecting ≥5 mL change in CTP volume between consecutive scans (sensitivity, 0.76; specificity, 0.86) and was more accurate with smaller ICH, thalamic hemorrhage, and homogeneous clots. Conclusions—: ABC/2 scores at local or central sites are sufficiently accurate to categorize ICH volume and assess eligibility for the CLEAR-III and MISTIE III studies and moderately accurate for change in ICH volume. However, accuracy decreases with large, irregular, or lobar clots. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: MISTIE-II NCT00224770; CLEAR-III NCT00784134.

1 July 2015 in NeuroImage
Verified
Journal Article
Closed access
JMJohn Muschelli
John Muschelli
NUNatalie L. Ullman
Natalie L. Ullman
WMW. Andrew Mould
W. Andrew Mould
PVPaul Vespa
Paul Vespa
DHDaniel F. Hanley
Daniel F. Hanley
CCCiprian M. Crainiceanu
Ciprian M. Crainiceanu